← All trials
NCT01906073
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2017
- Primary completion
- Nov 1, 2020
- Completion date
- Dec 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 108
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Norwegian University of Science and TechnologyLead sponsor
- Norwegian University of Science and TechnologyStudy director
- L'Hospitalet de LlobregatCollaborator
- Flinders UniversityCollaborator
- Norwegian University of Science and TechnologyCollaborator
- University of MilanCollaborator
- Maastricht UniversityCollaborator
- University of BonnCollaborator
- Cantonal Hospital of St. GallenCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.